CD274 and non-small cell lung carcinoma: Similarly, BI 754111, an mAb for LAG-3, was also tested with BI 754091 (anti-PD-1) in treatment-refractory solid tumors, in a dose escalation phase 1 study, followed by an expansion phase in microsatellite stable (MSS) CRC and anti-PD1/PD-L1 refractory tumors including NSCLC (NCT03156114) (Johnson et al., 2020).